InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the full record of transactions filed by Lukatch Heath, Director. Director active across 3 companies, notably Inogen Inc. In total, 15 disclosures have been logged. Activity tracked since 10 May 2021. The latest transaction was disclosed on 12 June 2025 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Lukatch Heath
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations15 total
3,041 shares0Common StockSEC:0001596385-25-000004:0
6,000 shares@ US$16.0016.3% of flowCommon StockSEC:0001649094-25-000051:0
1,550 shares0Common StockSEC:0001649094-24-000012:0
5,000 shares@ US$16.0013.8% of flowCommon StockSEC:0001415889-24-002320:0
4,000 shares@ US$16.0011.0% of flowCommon StockSEC:0001415889-24-002058:0
13,000 shares@ US$16.0035.1% of flowCommon StockSEC:0001209191-24-000783:0
2,500 shares0Common StockSEC:0001209191-23-037508:0
315 shares@ US$16.000.9% of flowCommon StockSEC:0001209191-23-003152:0
335 shares@ US$16.000.9% of flowCommon StockSEC:0001209191-22-061256:0
4,335 shares@ US$16.0012.9% of flowCommon StockSEC:0001209191-22-057030:0
3,015 shares@ US$16.009.1% of flowCommon StockSEC:0001209191-22-054664:0
3,125 shares0Common StockSEC:0001209191-22-034061:0
9,000 shares@ US$8.50100.0% of flowCommon StockSEC:0001209191-21-065719:0
4,500 shares0Common StockSEC:0001209191-21-043546:0
2,754 shares0Common StockSEC:0001209191-21-032227:0
15 of 15 declarations
About Lukatch Heath
Lukatch Heath is Administrateur and has filed 15 disclosures in total. In the sampled recent filings spanning 2021-05-12 to 2025-06-16, sales amount to EUR 67292, the most common transaction nature is Levée d'options, and the main filings concern Vaxcyte, Inc. and Flexion Therapeutics Inc.
